Y mAbs Therapeutics Cash Flow-to-Debt Ratio
Y mAbs Therapeutics cash flow-to-debt ratio. Y mAbs Therapeutics (YMAB) has a Cash Flow-to-Debt Ratio of 0.06x as of June 2025, meaning its operating cash flow of $1.65 Million could theoretically repay 0% of its total liabilities ($29.72 Million) in one year. Check how high is Y mAbs Therapeutics's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Y mAbs Therapeutics (2016–2024)
Cash flow-to-debt ratio of Y mAbs Therapeutics from 2016 to 2024. Historical debt coverage capacity for Y mAbs Therapeutics across 9 annual periods. Check Y mAbs Therapeutics cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Y mAbs Therapeutics Cash Flow-to-Debt Ratio by Year (2016–2024)
Y mAbs Therapeutics cash flow-to-debt ratio by year from 2016 to 2024. Year-by-year debt coverage analysis for Y mAbs Therapeutics. For the full cash flow conversion analysis, see cash efficiency ratio of Y mAbs Therapeutics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.56x | $-15.71 Million | $27.90 Million | ▲ +44.4% |
| 2023 | -1.01x | $-27.23 Million | $26.88 Million | ▲ +57.0% |
| 2022 | -2.36x | $-75.92 Million | $32.23 Million | ▲ +25.0% |
| 2021 | -3.14x | $-102.56 Million | $32.68 Million | ▲ +9.8% |
| 2020 | -3.48x | $-91.23 Million | $26.21 Million | ▲ +17.3% |
| 2019 | -4.21x | $-73.50 Million | $17.46 Million | ▼ -16.3% |
| 2018 | -3.62x | $-41.23 Million | $11.40 Million | ▼ -127.4% |
| 2017 | -1.59x | $-15.87 Million | $9.97 Million | ▲ +25.9% |
| 2016 | -2.15x | $-11.17 Million | $5.20 Million | — |